Neurofem Injection 500 Milligrams (Meropenem Hydrate)

Adult administration

As Meropenem Hydrate, administer 0.5 to 1 g (potency) daily, divided into 2 to 3 doses by slow intravenous infusion over more than 30 minutes. For suspected infections in patients with pathogenic pneumonia, peritonitis, and neutropenia, administer 1 g (potency) via slow intravenous infusion every 8 hours. For cystic fibrosis and meningitis, administer 2 g (potency) via slow intravenous infusion every 8 hours.

Child administration

For bacterial meningitis in children over 3 months, administer 40 mg per kg of body weight via slow intravenous infusion over more than 30 minutes every 8 hours, depending on the susceptibility of the pathogens and the patient's condition and the type of infection.

This medication should not be used in patients who have had shock induced by this drug in the past. Also, patients taking valproate sodium, an antiepileptic drug, should be cautious as this drug may lower valproate blood levels, potentially causing seizures to recur. Patients with a history of hypersensitivity to this drug or its ingredients, as well as those with severe allergic reactions to other carbapenem antibiotics or beta-lactam antibiotics (such as penicillins, cephalosporins), should not receive this medication. Patients with allergic constitutions, asthma, or those prone to allergic reactions such as rashes should use this drug with caution. Patients with impaired renal function may have the drug remain in their body longer, leading to central nervous system side effects, necessitating adjustments in dosage or administration intervals. Patients with epilepsy or central nervous system disorders are also at risk for seizures or consciousness disturbances, requiring careful monitoring. Extreme caution is warranted in patients with severe liver dysfunction, the elderly, and infants (especially those under 3 months), and those in poor nutritional states or who have difficulty ingesting food orally should be monitored closely. This drug can rarely cause a range of side effects such as shock, anaphylaxis, severe skin rashes, blood abnormalities, liver dysfunction, kidney impairment, gastrointestinal issues, central nervous system symptoms, and respiratory problems, so patient status should be observed closely during administration. If symptoms such as rashes, breathing difficulties, seizures, severe diarrhea, or signs of liver dysfunction occur, the administration should be immediately halted and appropriate treatment should be provided. To prevent the emergence of resistant bacteria, this drug should only be used for the minimum necessary duration based on susceptibility testing, which should be performed within 3 days of initiating treatment; if the tests are unsuitable, a different drug should be considered. Prior to administration of this drug, it is essential to check the patient's history for allergies to beta-lactam drugs, and during treatment to closely monitor the patient for potential shock. Caution is also required when this drug is used in combination with probenecid, antiepileptic drugs, hormonal contraceptives, or warfarin, especially when used with warfarin as blood coagulation status must be assessed frequently. Pregnant women or those who may become pregnant should only use this drug if its benefits are deemed to outweigh its risks, as its safety during pregnancy has not been established; breastfeeding mothers are advised to avoid breastfeeding as the drug may be secreted in breast milk. The safety and efficacy for infants under 3 months have not been confirmed, and caution should be exercised in their use. Elderly patients are at increased risk of side effects due to decreased bodily functions and should have their dosage and administration intervals adjusted accordingly, with careful monitoring of their status due to the risk of bleeding associated with vitamin K deficiency. This drug is administered only via intravenous injection, and should be used as soon as possible after reconstitution. It should be used within 6 hours at room temperature or within 24 hours if refrigerated. Headaches, dizziness, or mental confusion may occur during driving or operation of machinery, and caution is needed.

Serious side effects

Shock, anaphylaxis, severe allergic reactions, severe skin reactions, toxic epidermal necrolysis (Lyell syndrome), Stevens-Johnson syndrome, drug reaction (DRESS syndrome), erythema multiforme, acute generalized exanthematous pustulosis (AGEP), fulminant hepatitis, liver failure, jaundice, acute renal failure, severe renal impairment, severe colitis, seizures, consciousness disturbances, central nervous system symptoms, asthma, respiratory distress, pulmonary edema, epilepsy.

Mild side effects

• Oral discomfort
• dizziness
• changes in stool
• tinnitus
• sweating
• rash
• hives
• heat sensation
• erythema
• itching

This drug should be stored in a sealed container to protect it from air, ideally at room temperature between 1 to 30 degrees Celsius. Proper storage will help maintain its efficacy for a longer period.

Appearance

A colorless and transparent vial filled with crystalline powder that is white to pale yellow.

Package unit

10 vials/box